In its May 2026 quarter, NanoViricides maintained steady operations with stock-based compensation for advisory and director services and no defaults, positioning the company to progress NV-387 into Phase II clinical efficacy studies. The company’s proprietary nanoviricide technology mimics host cell structures to neutralize viruses directly, showing broad-spectrum preclinical activity against respiratory viruses and orthopoxviruses including measles and MPox. Despite being pre-revenue and reliant on partnerships—such as with Karveer Meditech in India—and external financing, NanoViricides’ integrated manufacturing and diversified antiviral pipeline address significant unmet medical needs. Key near-term milestones include Phase II trial initiations and regulatory filings, while clinical development risks and liquidity management remain critical watchpoints.